Biomea Fusion, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMEA research report →
Range $10 – $40
Price Chart
About the company
Biomea Fusion, Inc. , a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
- CEO
- Michael J. Hitchcock
- IPO
- 2021
- Employees
- 34
- HQ
- San Carlos, CA, US
Get TickerSpark's AI analysis on BMEA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $41.75M
- P/E
- -1.82
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 5.50
- EV/EBITDA
- -0.71
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -131.27%
- ROIC
- -317.22%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,409,000+0.0%
- Op Income
- $-81,307,000
- Net Income
- $-61,797,000+55.4%
- EPS
- $-1.18+69.2%
- OCF Growth
- +41.3%
- FCF Growth
- +41.5%
- 52W High
- $2.24
- 52W Low
- $0.45
- 50D MA
- $1.00
- 200D MA
- $1.32
- Beta
- -0.30
- RSI (14)
- 39
- Avg Volume
- 2.22M
No earnings-call transcripts are available for BMEA yet.
- Free Float
- 93.2%
- Shares Outstanding
- 72.68M
- Float Shares
- 67.76M
of shares held by institutions
65 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 8.82M | ▲ 1.19K |
| Marshall Wace, Llp | 3.07M | ▲ 1.02M |
| Vanguard Group Inc | 2.97M | ▲ 797.98K |
| Vanguard Capital Management LLC | 2.83M | 0 |
| Aisling Capital Management LP | 2.05M | 0 |
| Mariner, LLC | 1.57M | ▲ 971.58K |
| Renaissance Technologies LLC | 1.16M | ▼ 292.76K |
| Blackrock, Inc. | 734.27K | ▲ 18.82K |
| Geode Capital Management, LLC | 731.17K | ▲ 22.32K |
| Susquehanna International Group, Llp | 612.74K | ▼ 17.13K |
| Arrowstreet Capital, Limited Partnership | 454.62K | ▲ 454.62K |
| Ubs Group AG | 416.17K | ▼ 28.55K |
Held by 35 ETFs
Biggest fund positions in BMEA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | Faust Elizabeth | other | 196,299 |
| Jun 10, 26 | AGUIAR ERIC | other | 196,299 |
| Jun 10, 26 | Ray Sumita | other | 196,299 |
| Jun 10, 26 | Averill Julianne | other | 173,711 |
| Apr 1, 26 | Erdtmann Rainer M | other | 452,512 |
| Apr 1, 26 | Hitchcock Michael J.M. | other | 667,477 |
| Dec 31, 25 | Erdtmann Rainer M | other | 0 |
| Dec 31, 25 | Erdtmann Rainer M | other | 50,600 |
| Dec 31, 25 | Erdtmann Rainer M | other | 50,000 |
| Dec 31, 25 | Erdtmann Rainer M | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BMEA coverage
Recent articles, reports, and earnings notes.
No research on BMEA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BMEA report →Biomea Fusion to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 12
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · Nov 10
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
globenewswire.com · Nov 10
Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
defenseworld.net · Oct 15
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
marketbeat.com · Oct 13
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
seekingalpha.com · Oct 13
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
globenewswire.com · Oct 13
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
globenewswire.com · Oct 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.